Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 8:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 48,954 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Treatment 1 Clear all
Recruiting Phase 3 Interventional

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

NCT05821959
View directory record Official record
Conditions
Sensorineural Hearing Loss, Bilateral
Interventions
AAVAnc80-hOTOF via Akouos Delivery Device, AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
Combination Product
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
San Francisco, California • Iowa City, Iowa • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 4, 2026, 8:35 AM EDT
Suspended Phase 2 Interventional

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

NCT05904080
View directory record Official record
Conditions
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
92
States / cities
Irvine, California • Los Angeles, California • Newport Beach, California + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 4, 2026, 8:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neuromodulation and Neuroimaging in Older Children With Mild Traumatic Brain Injury

NCT05762796
View directory record Official record
Conditions
Brain Concussion, Mild Traumatic Brain Injury, Motor Disorders, Cognitive Impairment
Interventions
tDCS in Youth with mild traumatic brain injury
Device
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
10 Years to 15 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 4, 2026, 8:35 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Molding Process

NCT03605303
View directory record Official record
Conditions
Refractive Error Correction
Interventions
Test/Control, Control/Test
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 4, 2026, 8:35 AM EDT
Recruiting Not applicable Interventional

Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders

NCT05929703
View directory record Official record
Conditions
Delirium, Neurocognitive Disorders, Mild Cognitive Impairment, Alzheimer Disease, Aging, Family Support, Family Members, Caregiver Burden, Implementation Science, Patient Satisfaction
Interventions
HELP, FAM-HELP
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
70 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Orange, California • Portland, Maine • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Phase 3 Interventional Results available

Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

NCT02877927
View directory record Official record
Conditions
Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions
Omadacycline, Linezolid
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Not applicable Interventional

Effects of Animal Assisted Activity on Biobehavioral Stress Responses of Hospitalized Children: A Randomized Control Trial

NCT03017027
View directory record Official record
Conditions
Psychosocial Stress
Interventions
Therapy dog visitation (TDV), non-TDV control
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 4, 2026, 8:35 AM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Ph1 Study of Valortim and Ciprofloxacin in Humans

NCT00964561
View directory record Official record
Conditions
Anthrax
Interventions
Ciprofloxacin and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim
Drug · Other
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Phase 4 Interventional

Intravenous (IV) Pantoprazole in Erosive Esophagitis

NCT00133770
View directory record Official record
Conditions
Esophagitis
Interventions
pantoprazole
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy

NCT00063570
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Pemetrexed, Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
6
States / cities
Aurora, Colorado • Plantation, Florida • Morrisville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2009 · Synced Oct 4, 2026, 8:35 AM EDT
Recruiting Phase 2 Interventional

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

NCT07837973
View directory record Official record
Conditions
Overweight , Obesity, Adults
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Tempe, Arizona • Oceanside, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Phase 2 Interventional

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

NCT00151073
View directory record Official record
Conditions
Hormone-Refractory Prostate Cancer
Interventions
Zoledronic acid, Estramustine, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 4, 2026, 8:35 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

NCT06381141
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CLN-619
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Not applicable Interventional Results available

Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy

NCT05022641
View directory record Official record
Conditions
Parathyroid Adenoma, Parathyroid Neoplasms, Parathyroid Cancer, Hypercalcemia, Primary Hyperparathyroidism
Interventions
PTeye, Standard of Care
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Phase 3 Interventional

Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia

NCT00186966
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome), Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan, Hematopoietic stem cell transplant, Total body irradiation
Drug · Procedure · Radiation
Lead sponsor
Dutch Childhood Oncology Group
Other
Eligibility
Up to 18 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

NCT00839956
View directory record Official record
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
Interventions
Bortezomib, Vorinostat
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

NCT04283656
View directory record Official record
Conditions
Transgender Health, Gender Dysphoria, Transgender Women, Human Immunodeficiency Virus
Interventions
Doravirine/Lamivudine/Tenofovir, Spironolactone 100mg, Estradiol 2mg, Placebo
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02637856
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
67
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Perinatal Depression

NCT06525922
View directory record Official record
Conditions
Perinatal Depression
Interventions
Center M
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

NCT01175122
View directory record Official record
Conditions
Influenza A Virus Infection
Interventions
H2N3 MO 2003/AA ca Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 42 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Phase 2 Interventional

Treatment of Suicidal Women With Borderline Personality Disorder

NCT00183651
View directory record Official record
Conditions
Borderline Personality Disorder, Suicide
Interventions
Standard dialectical behavior therapy (SDBT), Individual DBT with no DBT group sessions (DBT-I), Group Skills DBT with no DBT individual sessions (DBT-S)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 4, 2026, 8:35 AM EDT
Completed Not applicable Interventional

Values and Options in Cancer Care 2 (VOICE 2) A Randomized Pilot Study

NCT05352451
View directory record Official record
Conditions
Communication, Multidisciplinary
Interventions
Interventional Survey
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 4, 2026, 8:35 AM EDT
Active, not recruiting Phase 1 Interventional

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT01375829
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Ixabepilone, Pharmacological Study, Temsirolimus
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 8:35 AM EDT
Active, not recruiting Phase 2 Interventional

Allogeneic BM-MSCs in Patients With Painful Lumbar Facet Arthropathy

NCT06001853
View directory record Official record
Conditions
Facet-Mediated Low Back Pain, Lumbar Facet Joint Osteoarthritis
Interventions
BM-MSC injection, DSMO Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 4, 2026, 8:35 AM EDT